Clinical StudiesA Preliminary Report: Radical Surgery and Stem Cell Transplantation for the Treatment of Patients With Pancreatic CancerOmazic, Brigitta*,✠; Ayoglu, Burcu†; Löhr, Matthias‡; Segersvärd, Ralf‡; Verbeke, Caroline§; Magalhaes, Isabelle∥; Potacova, Zuzana¶; Mattsson, Jonas¶; Terman, Alexei§; Ghazi, Sam§; Albiin, Nils#; Kartalis, Nikolaos#; Nilsson, Peter†; Poiret, Thomas∥; Zhenjiang, Liu∥; Heuchel, Rainer‡; Schwenk, Jochen M.†; Permert, Johan‡; Maeurer, Markus J.∥; Ringden, Olle∥ Author Information *Division of Clinical Immunology and Transfusion Medicine ¶Center for Allogeneic Stem Cell Transplantation ∥Division of Therapeutic Immunology (TIM) Departments of §Laboratory Medicine, Division of Pathology ‡Surgical Gastroenterology #Radiology, Karolinska Institutet, Karolinska University Hospital Huddinge †Affinity Proteomics, SciLifeLab, School of Biotechnology, KTH-Royal Institute of Technology, Stockholm, Sweden ✠Deceased. This report is dedicated in memoriam to Dr Brigitta Omazic. J.P., M.L., M.J.M., and O.R. contributed equally. B.O., J.P., M.J.M., O.R.: conception and design. All authors: collection and assembly of data. B.O., M.L., M.J.M., O.R.: data analysis and interpretation. B.O., M.L., M.J.M., O.R.: manuscript writing. All authors: final approval of manuscript. Reprints: Markus J. Maeurer, Division of Therapeutic Immunology (TIM), Karolinska Institutet, Karolinska University Hospital Huddinge, Hälsovägen F79, SE-14186 Stockholm, Sweden. E-mail: [email protected]. Journal of Immunotherapy 40(4):p 132-139, May 2017. | DOI: 10.1097/CJI.0000000000000164 Buy SDC Metrics Abstract We examined the immunologic effects of allogeneic hematopoietic stem cell transplantation (HSCT) in the treatment of pancreatic ductal adenocarcinoma, a deadly disease with a median survival of 24 months for resected tumors and a 5-year survival rate of 6%. After adjuvant chemotherapy, 2 patients with resected pancreatic ductal adenocarcinoma underwent HSCT with HLA-identical sibling donors. Comparable patients who underwent radical surgery, but did not have a donor, served as controls (n=6). Both patients developed humoral and cellular (ie, HLA-A*01:01-restricted) immune responses directed against 2 novel tumor-associated antigens (TAAs), INO80E and UCLH3 after HSCT. Both TAAs were highly expressed in the original tumor tissue suggesting that HSCT promoted a clinically relevant, long-lasting cellular immune response. In contrast to untreated controls, who succumbed to progressive disease, both patients are tumor-free 9 years after diagnosis. Radical surgery combined with HSCT may cure pancreatic adenocarcinoma and change the cellular immune repertoire capable of responding to clinically and biologically relevant TAAs. Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.